- Cubist Pharmaceuticals (CBST) is out with top-line data from a pivotal study of ceftolozane/tazobactam in complicated intra-abdominal infections.
- The company says the Phase 3 trial met the FDA and EMA's primary endpoint (non-inferiority to meropenem).
- AE profile is "consistent with that seen with other cephalosporin antibiotics and comparable to meropenem."
- NDA expected in H1 2014. MAA expected in H2 2014. (PR)
- CBST +10% premarket
Cubist Pharmaceuticals rallies as antibiotic candidate hits endpoint
Dec 16 2013, 09:18 ET